DISCOVER

Vascepa®

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

Vascepa


The History of Vascepa

Development of Vascepa leveraged Amarin’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The clinical development of Vascepa challenged previously established norms and created an important new drug that has the potential to significantly improve patient care for millions of patients. The use of Vascepa is now supported by over 200 issued patents worldwide and by FDA designation of the active ingredient in Vascepa as a new chemical entity under its regulatory regime. This designation from FDA was the first recognition that no FDA-approved drug has the same active ingredient as Vascepa.

MORE

recent news


05 Nov 2019

Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations MORE

04 Nov 2019

Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented at American Heart Association’s 2019 Scientific Sessions, November 16 – 18 MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$17.48
Change:
+0.72
Date:
4:00 PM EDT, Nov 8, 2019
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe